mds-2026-prodromal-early-onset-parkinson-biomarkers

MDS 2026 — Prodromal and Early-Onset Parkinson's Biomarkers

Congress: Movement Disorder Society (MDS) International Congress 2026 Dates: October 4-8, 2026 Location: Seoul, Korea — COEX Convention and Exhibition Center Theme: Understanding Aging in Movement Disorders

Overview

MDS 2026 — Prodromal and Early-Onset Parkinson's Biomarkers

Congress: Movement Disorder Society (MDS) International Congress 2026 Dates: October 4-8, 2026 Location: Seoul, Korea — COEX Convention and Exhibition Center Theme: Understanding Aging in Movement Disorders

Overview

The MDS 2026 Congress features groundbreaking research on prodromal and early-onset Parkinson's disease (PD), with particular emphasis on biomarker-driven early detection, risk stratification, and understanding the progression from preclinical to clinical disease. These advances represent a critical shift toward preventive neurology in movement disorders.

This page covers:

• REM sleep behavior disorder (RBD) as the strongest prodromal marker
• Olfactory dysfunction and DAT imaging for early detection
• Genetic markers (GBA, LRRK2, SNCA) in prodromal and early-onset PD
• Fluid biomarkers for disease progression prediction
• Clinical progression markers and risk stratification

REM Sleep Behavior Disorder as Prodromal Marker

Background

REM sleep behavior disorder (RBD) is the strongest prodromal marker for Parkinson's disease and related synucleinopathies. First described in 1996 by Schenck et al., longitudinal studies have demonstrated that 80-90% of individuals with idiopathic RBD eventually develop a neurodegenerative disorder[@schenck1996][@iranzo2014].

Key MDS 2026 Topics

• Isolated RBD (iRBD) without other prodromal features
• RBD with olfactory dysfunction
• RBD with autonomic dysfunction

Clinical Implications

| RBD Feature | Progression Risk | Time to Conversion |
|-------------|------------------|--------------------|
| iRBD alone | 80-90% over 15 years | 10-20 years |
| iRBD + hyposmia | >90% | 5-10 years |
| iRBD + autonomic dysfunction | >95% | 5-15 years |
| iRBD + subtle motor signs | >95% | 3-10 years |

See also: [REM Sleep Behavior Disorder](/diseases/rem-sleep-behavior-disorder), [Prodromal Parkinson's Disease](/diseases/prodromal-parkinsons)

Olfactory Dysfunction and DAT Imaging

Olfactory Testing

Olfactory dysfunction is often the earliest detectable marker in prodromal PD, preceding motor symptoms by years to decades[@simun2025]:

• University of Pennsylvania Smell Identification Test (UPSIT): Gold standard
• Sniffin' Sticks Test: European validation
• Olfactory event-related potentials: Objective assessment

Dopamine Transporter Imaging

DAT-SPECT (DaTscan) imaging provides objective assessment of dopaminergic integrity:

Combined Approach

The combination of olfactory testing and DAT imaging significantly improves predictive accuracy for prodromal PD identification[@simun2025]:

• Olfactory dysfunction + normal DAT: Moderate risk
• Normal olfaction + abnormal DAT: Moderate risk
• Olfactory dysfunction + abnormal DAT: Very high risk (>90%)

Genetic Markers in Prodromal and Early-Onset PD

GBA Variants

Heterozygous [GBA](/genes/gba) variants significantly modify prodromal marker expression and disease progression[@gba2025]:

| GBA Variant | Effect on Prodromal Phase | Early-Onset Risk |
|-------------|---------------------------|------------------|
| N370S | Earlier RBD onset, more severe hyposmia | Higher |
| L444P | Rapid progression through prodromal phase | Highest |
| E326K | Subtle prodromal markers | Moderate |
| T369M | Late-onset, mild prodromal features | Lower |

Key Findings for GBA Carriers:

• Earlier onset of RBD (mean age 50 vs. 60 in non-carriers)
• More rapid progression from prodromal to clinical PD
• More severe non-motor symptoms (cognitive, autonomic)
• Lower GCase activity correlates with marker severity

LRRK2 Variants

[LRRK2](/genes/lrrk2) carriers demonstrate distinct prodromal phenotypes[@lrrk22025]:

• G2019S Carriers: Later onset of prodromal features, typically typical PD phenotype
• Penetrance: Age-dependent, ~30% by age 80
• Prodromal Features: Less prominent RBD, more typical tremor-dominant presentation
• Response: Generally good levodopa response

• LRRK2 kinase activity can be measured in peripheral blood cells
• Phospho-LRRK2 as potential biomarker for disease activity
• May benefit from kinase inhibitor therapy in prodromal phase

SNCA Variants

[SNCA](/genes/snca) multiplication and point mutations are associated with aggressive prodromal courses:

• SNCA Duplications: Early-onset, rapid progression, prominent dementia
• Point Mutations (A30P, E46K, A53T): Variable expressivity
• Alpha-Synuclein Seed Amplification: Positive in prodromal phase[@snca2025]

• Earlier age of prodromal marker onset
• More severe cognitive involvement
• Higher rate of progression to dementia

Fluid Biomarkers in Early PD

Neurofilament Light Chain (NfL)

NfL is a sensitive marker of axonal injury and correlates with disease progression in prodromal and early PD[@nfl2025]:

| Stage | CSF NfL | Blood NfL | Significance |
|-------|---------|-----------|--------------|
| Prodromal | Normal to mildly elevated | Variable | Early neuronal injury |
| Early PD | Moderately elevated | Elevated | Active neurodegeneration |
| Established PD | High | High | Disease severity |

Prognostic Value:

• Higher baseline NfL predicts faster progression
• Serial measurements track treatment response
• NfL trajectory informs clinical trial endpoints

Phosphorylated Alpha-Synuclein (pSer129)

pSer129 is the major pathological form of alpha-synuclein and a key biomarker[@pser1292025]:

• Elevated in: Prodromal PD, especially RBD-positive
• Sensitivity: 80-90% in prodromal PD
• Specificity: >90% for synucleinopathies
• Correlation: Disease severity and progression rate

Alpha-Synuclein Seed Amplification Assays (αSyn-SAA)

Seed amplification represents the most significant advance in prodromal PD biomarkers:

• RT-QuIC: Detects pathological alpha-synuclein in CSF
• PMCA: Alternative amplification technique
• Application: Positive in ~90% of iRBD converters
• Utility: Confirmation of synucleinopathy in prodromal phase

Emerging Fluid Biomarkers

Clinical Progression Markers

MDS Prodromal Criteria

The MDS research criteria integrate multiple markers for probability calculation[@berg2015][@pavlin2025]:

| Marker | Likelihood Ratio |
|--------|------------------|
| Definite RBD | High |
| Olfactory loss | Moderate-High |
| Subtle motor signs | Moderate |
| Autonomic dysfunction | Moderate |
| Depression | Low-Moderate |
| Genetic risk | Variable |

Progression Prediction Models

Early-Onset PD Characteristics

Early-onset PD (onset <50 years) has distinct features:

| Feature | Early-Onset | Late-Onset |
|---------|-------------|------------|
| Genetic etiology | Higher (GBA, LRRK2, SNCA) | Lower |
| Family history | More common | Less common |
| Progression | Slower motor, more cognitive | More rapid motor |
| Treatment response | Good initially | Good |
| Non-motor features | Prominent early | Variable |

See: [Parkinson's Disease Subtypes](/diseases/parkinsons-subtypes)

Session Highlights

Expected Presentations

Key Questions Addressed

• How to optimize prodromal PD identification in clinical practice?
• Which biomarkers best predict conversion from prodromal to clinical PD?
• What is the optimal timing for neuroprotective intervention?
• How to stratify prodromal individuals for clinical trials?

Clinical Implications

For Clinicians

For Researchers

For Patients

Cross-References

Related Pages

• [MDS 2026 — Parkinson's Disease Diagnostics & Biomarkers](/events/mds-2026-parkinsons-diagnostics-biomarkers)
• [MDS 2026 — Main Congress Page](/events/mds-2026)
• [MDS 2026 — GBA and LRRK2 Genetic Susceptibility](/events/mds-2026-gba-lrrk2-genetic-susceptibility)
• [Prodromal Parkinson's Disease](/diseases/prodromal-parkinsons)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [REM Sleep Behavior Disorder](/diseases/rem-sleep-behavior-disorder)
• [GBA Gene](/genes/gba)
• [LRRK2 Gene](/genes/lrrk2)
• [SNCA Gene](/genes/snca)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Biomarkers for Parkinson's Disease](/mechanisms/biomarkers-parkinsons)

Mechanisms

• [Alpha-Synuclein Pathology](/mechanisms/alpha-synuclein)
• [Lysosomal Dysfunction](/mechanisms/lysosomal-dysfunction)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Neuroinflammation](/mechanisms/neuroinflammation-across-neurodegeneration)

References

External Links

• [MDS Congress 2026](https://www.mdscongress.org)
• [Parkinson's Progression Markers Initiative (PPMI)](https://www.ppmi-info.org/)
• [Michael J. Fox Foundation - Prodromal Research](https://www.michaeljfox.org/)
• [MDS Prodromal Parkinson's Criteria](https://www.movementdisorders.org/)
• [International RBD Study Group](https://www.rbdsg.org/)